Butikacin is deoxystreptamine aminoglycoside with bactericidal activity with good activity against Staphylococcus aureus and a range of gram-negative bacteria.

Fuzlocillin is a penicillin antibiotic. This semisynthetic acylureidopenicillin with antibacterial activity binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. Fuzlocillin (furazlocillin), has been shown to be highly specific for the FtsI gene. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This interrupts bacterial cell wall synthesis and results in the weakening of the bacterial cell wall, eventually causing the cell to break down (cell lysis). Among the acylureidopenicillins, furaclocillin exerts increased activity against Escherischia coli, Klebsiella, Proteus and Pseudomonas aeruginosa.

Merimepodib has immunosuppressive activity. It targets hepatitis C indirectly through the inhibition of inositol monophosphate dehydrogenase, which exerts an acute antiproliferative effect on lymphocyte proliferation due to their almost exclusive dependence on the de novo pathway for synthesis of guanosine. Phase II clinical trial study of merimepodib for the treatment of HCV infection and psoriasis were completed. The poor pharmacokinetic-pharmacodynamic results have resulted in discontinuation of clinical trials.

Cefoxazole is a semi-synthetic, first-generation cephalosporin with bactericidal activity against penicillin-resistant strains of S. aureus and used in the treatment of bovine mastitis.

Cefivitril is a semi-synthetic cephalosporin with broad antibacterial activity against penicillin-resistant strains of S. aureus. Compared with the other cephalosporin, Cefivitril showed a better in vitro activity on gram pos. and gram neg. bacteria. Sensitivity tests were performed with 1007 bacterial strains to evaluate the in vitro activity of Cefivitril compared with that of cefuroxime and cephapirin. Compared with cefuroxiime and cephaprin, Cefivitril activity was significantly higher on Pasteurella and Salmonella, whereas no significant differences were detected for Streptococcus, Proteus, and Pseudomonas.

Cefempidone is a broad-spectrum cephalospolin antibiotic

Pramiconazole is a novel azole with potent antifungal activity against yeasts, dermatophytes and many other fungal species. It is a new addition to the family of triazole antifungal agents that act by inhibiting fungal cell membrane ergosterol synthesis, thereby leading to increased cell permeability and destruction. In preclinical studies, pramiconazole exhibited similar or superior antifungal activity to ketoconazole and itraconazole, and selectively inhibited ergosterol synthesis with a broad spectrum activity. Pramiconazole was absorbed rapidly and had a long half-life, allowing for once-daily dosing. In phase I and II clinical trials, pramiconazole reduced the growth of Candida albicans, Malassezia globosa, Microsporum canis, Trichophyton mentagrophytes and Trichophyton rubrum, and was generally well tolerated. Pramiconazole is a well-tolerated and effective treatment for pityriasis versicolor.

Etisomicin is a semisynthetic aminoglycoside antibiotic.

Esafloxacin (7-(3-amino-1-pyrrolidinyl)-1-ethyl-6-fluoro-1,4 -dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid) is an antibacterial agent.

Salazosulfathiazole was developed as a sulfonamide with the antibacterial and antirheumatic properties. Information about the current use of this drug is not available.